S268: SAFETY, TOLERABILITY, AND PHARMACOKINETIC/PHARMACODYNAMIC RESULTS FROM PHASE 1 STUDIES OF GBT021601, A NEXT-GENERATION HBS POLYMERIZATION INHIBITOR FOR TREATMENT OF SICKLE CELL DISEASE. (23rd June 2022) - Brown, C.; Key, C.; Agodoa, I.; Olbertz, J.; Duchin, K.; Barth, A.; Lisbon, E.